Scribe Therapeutics, a CRISPR-focused developer targeting cardiovascular and metabolic diseases, priced an upsized IPO at the top end of its range, raising about $129 million. The company began trading on Nasdaq under ticker SCTX, with shares opening above the offering price and finishing the day sharply higher. The pricing reinforces continued appetite for gene-editing exposure, even as clinical proof and financing discipline remain key watchpoints for investors. Scribe’s post-IPO trading performance highlights how the market is still rewarding platforms positioned in large chronic-disease markets.